Trexquant Investment’s Co-Diagnostics CODX Stock Holding History

Trexquant Investment’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-886	Closed	-$164K	–	1565
2022 Q1	$164K	Buy	+886	New	+$183K	0.01%	1232

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trexquant Investment's CODX Position: Q2 2022 in Review

Trexquant Investment sold out of Co-Diagnostics (CODX) in Q2 2022, closing a stake of 886 shares — an estimated $164K sold.

Trexquant Investment first reported a position in CODX in Q1 2022 and held it in 1 quarter. The position peaked at $164K in Q1 2022. 69 funds tracked by Wall St. Rank hold CODX as of Q2 2022.

Trexquant Investment reported no remaining Co-Diagnostics position as of Q2 2022 after selling out during the quarter.
Trexquant Investment sold 886 Co-Diagnostics shares in Q2 2022, an estimated $164K.
Trexquant Investment first reported a position in Co-Diagnostics in Q1 2022 and held it in 1 quarter.
Trexquant Investment's Co-Diagnostics position peaked at $164K in Q1 2022.
69 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.